Intervention: Vorinostat
Trial phase: Phase 1
ATC code: L01XH01
SMILES: O=C(CCCCCCC(=O)Nc1ccccc1)NO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.

vorinostat: Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.

Correlative studies: Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at C2D1 (≈3 mos.), C3D1 (≈4 mos.), C5D1 (≈6 mos.),C7D1 (≈8 mos.), and off study (ideally at ≈12 mos.)
Eligibility criteria:
DISEASE CHARACTERISTICS:

Must have received a BEAM (cytarabine, etoposide, melphalan, carmustine)-conditioned autologous stem cell transplantation for any of the following high-risk lymphomas:

Diffuse large B-cell lymphoma as defined by:

Induction failure but with response to salvage therapy
Relapse less than one year after completion of induction therapy
Elevated lactate dehydrogenase (LDH) at relapse
Stage III/IV disease at relapse
Positive PET scan after induction or salvage therapy
Age ≤ 75 and ≥ 60 years

Follicular lymphoma as defined by:

Progressive disease after two or more prior regimens
Transformed to aggressive lymphoma but still chemotherapy sensitive
Not felt to be a good candidate for an allogeneic transplantation

Hodgkin lymphoma as defined by:

Primary refractory disease
Relapse less than one year after completion of induction therapy
Relapse with PET-positive disease after salvage therapy
Relapsed refractory and not felt to be a good candidate for an allogeneic transplantation

Mantle cell lymphoma

Chemotherapy-sensitive disease after induction therapy
Chemotherapy-sensitive relapsed disease and not felt to be a good candidate for an allogeneic transplantation

T-cell non-Hodgkin lymphoma (NHL)

Peripheral T-cell lymphoma not otherwise specified and one or more of the following at diagnosis:

High LDH
Marrow involvement
Age > 60 years
Low platelet count
Relapsed chemotherapy-sensitive disease
Angioimmunoblastic lymphadenopathy with dysproteinemia
Anaplastic lymphoma kinase-negative anaplastic NHL
Enteropathy-associated T-cell NHL
Natural killer (NK)/T-cell NHL and stage III/IV disease at diagnosis
NK blastic NHL

PATIENT CHARACTERISTICS:

ECOG (Eastern Cooperative Oncology Group) /WHO performance status 0-2
ANC (absolute neutrophil count) ≥ 1,000/μL
Platelet count ≥ 75,000/μL
Total bilirubin ≤ 1.5 mg/dL
AST (aspartate aminotransferase)/ALT (Alanine transaminase) ≤ 2 x upper limit of normal (ULN)
Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 50 mL/min
No severe or uncontrolled systemic illness
Patients must be able to swallow capsules
Negative pregnancy test
Not pregnant or nursing
Fertile patients must use at least two adequate barrier methods of contraception during study and for 90 days after completion of study therapy
No other malignancy within the past 5 years other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or a malignancy considered by their physician to be at less than 30% risk of relapse
No congenital long QT syndrome
No significant history of uncontrolled cardiac disease (i.e., uncontrolled hypertension, unstable angina, myocardial infarction within the past 6 months, or uncontrolled congestive heart failure)
No active bacterial, fungal, or viral infection
No known HIV infection
No active hepatitis B and/or hepatitis C infection
No other medical condition, including mental illness or substance abuse, deemed by the Investigator(s) to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results

PRIOR CONCURRENT THERAPY:

Recovered from the majority of the toxicities from the autologous transplantation (must have returned to their pretransplant baseline or have no greater than grade I extramedullary toxicity Common Toxicity Criteria for Adverse Effects[CTCAE 3.0])
No prior treatment with a histone deacetylase (HDAC) inhibitor (e.g., depsipeptide, MS-275, LAQ-824, belinostat, valproic acid)
More than 4 weeks since prior and no concurrent class Ia, Ib, or Ic antiarrhythmic drugs
No other concurrent antineoplastic chemotherapy or biologic therapy

No concurrent radiotherapy, unless for local control of bone pain

Irradiated area for pain management should be as small as possible and lesions within the irradiated field cannot be used for response
No concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of vorinostat (SAHA)